Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Hepatitis C virus (HCV) chronic infection can determine liver fibrosis, cirrhosis and hepatocellular carcinoma, as well as several extra-hepatic manifestations (i.e., mixed cryoglobulinemia, metabolic syndrome, kidney disease, etc.). HCV infection is asymptomatic until severe stages of disease, thus screening policy in the general population and in specific risk categories is necessary to allow for timely intervention. Despite a high sustained virological response by direct-acting antiviral drugs, a limited percentage of treated subject failed therapy according to resistance associated substitution carried on viral isolates and comorbidities in infected patients. Therefore, tailored therapy is required to cure HCV infection. Failure to comply with these conditions may impair success of HCV eradication expected by 2030. This Special Issue aims to discuss eradication perspectives related to therapy efficacy in patients with chronic diseases, developments in diagnostic procedures and improvements in screening policy.

Medicine --- Epidemiology & medical statistics --- HCV --- rheumatic --- interferon --- mortality --- hepatitis C virus (HCV) --- phylogeny --- resistance-associated substitution (RAS) --- chronic hepatitis C --- vibration controlled transient elastography --- fibrosis --- steatosis --- hepatocellular carcinoma --- hepatitis C --- genotype 3 --- liver cirrhosis --- pangenotypic --- children --- ledipasvir/sofosbuvir --- real-life --- sustained virological response --- elimination --- model --- COVID-19 --- PWID --- homeless persons --- HCV eradication --- direct-acting antivirals --- out-of-hospital --- retention in care --- HCV --- rheumatic --- interferon --- mortality --- hepatitis C virus (HCV) --- phylogeny --- resistance-associated substitution (RAS) --- chronic hepatitis C --- vibration controlled transient elastography --- fibrosis --- steatosis --- hepatocellular carcinoma --- hepatitis C --- genotype 3 --- liver cirrhosis --- pangenotypic --- children --- ledipasvir/sofosbuvir --- real-life --- sustained virological response --- elimination --- model --- COVID-19 --- PWID --- homeless persons --- HCV eradication --- direct-acting antivirals --- out-of-hospital --- retention in care

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Cardiology and cardiovascular sciences are two rapidly growing areas in medicine, with heart diseases being the number one cause of death worldwide. The last four decades have witnessed many developments in various cardiological sciences, including coronary artery disease, valve disease, heart failure, congenital heart diseases, and cardiovascular imaging, with a number of newly developed concepts, such as cardio-oncology, cardio-renal diseases, and preventive cardiology. This Special Issue (SI) of the Journal of Clinical Medicine, entitled “JCM-Advances in Cardiology”, focuses on recent advances in the cardiological sciences. It published 8 research articles of significant clinical and scientific value.

Medicine --- Pharmacology --- ST segment elevation myocardial infarction --- COVID-19 --- primary percutaneous intervention --- Coptic clergy --- mortality --- cardiovascular risk factors --- prevalence --- major adverse events --- obesity --- ACE2 --- renin–angiotensin system --- extraction --- reimplantation --- pacing --- ICD --- CRT --- dilated cardiomyopathy (DCM) --- LMNA --- lamin A --- lamin C --- next generation sequencing (NGS) --- myocarditis --- arrhythmias --- telemonitoring --- implantable cardioverter defibrillator --- implantable loop recorder --- Holter ECG --- metabolic-dysfunction-associated fatty liver disease (MAFLD) --- hepatic steatosis --- SteatoTest --- adipokines --- adiponectin --- visfatin --- cardiovascular disease --- n/a --- renin-angiotensin system

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Microalgae and seaweeds are a renewable source of potent bioactive ingredients with confirmed positive impacts on health and wellness. The interest in—and awareness of—the need to improve quality of life and well-being has led to a greater consumption of nutraceuticals, as well as the use of cosmeceuticals for “well-aging”. In this context, algae and microalgae are currently gaining immense popularity within the functional food, nutraceutical, and cosmeceutical industries. Recent advances in the characterization and evaluation of the biological properties of the whole material, fractions, or isolated compounds of algae and microalgae enable their use as ingredients for the development of novel nutraceutical and cosmeceutical products.

Medicine --- polysaccharides --- health benefits --- health risks --- biomedical --- polymer seasonal variation --- red seaweeds --- agarose --- agarotriose --- 3,6-anhydro-l-galactose --- prebiotics --- anti-colon cancer activity --- α-neoagarooligosaccharide hydrolase --- exo-acting 3,6-anhydro-α-(1,3)-L-galactosidase --- BpGH117 --- 3,6-anhydro-L-galactose --- human gut bacterium --- Bacteroides plebeius --- marine ingredients --- algae --- sensitive skin --- cosmetics --- seaweed --- protein --- extraction --- bioactive peptides --- industrial application --- marine macroalgae --- ingredients --- additives --- bioactives --- nutricosmetics --- Caulerpa racemosa --- Ulva lactuca --- nutritional --- potential --- SWE --- peloids --- microalgae --- cyanobacteria --- dermocosmetics --- mineral water --- seawater --- anti-obesity --- anti-inflammation --- anti-steatosis --- molecular networking

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Brown algae comprise approx. 2040 species grown in various climatic conditions. They represent a reservoir of various bioactive compounds, including fucoidan, alginate, phlorotannins, and fucoxanthins. They have shown an array of applications in pharmaceutical and medical fields. Hence, the Guest Editor invites all interested authors to submit their contributions to the current issue in Marine Drugs entitled “Bioactive Compounds from Brown Algae”. It aims to highlight different aspects of bioactive compounds found in brown algae, in either research or review articles. Specifically, we are interested in downstream processes, chemistry, biotechnology, and applications of, for example, heteropolysaccharides and other brown algae bioactives. In addition, the structure elucidation and enzymatic modification of these components are also within the scope of the present Issue.

hepatic steatosis --- lipogenesis --- seaweed --- polyphenol --- fucoidans --- fucoidanases --- glycosidic linkages --- molecular masses --- NMR --- structure–activity relationships --- fucoidan --- cancer --- VEGF --- gene expression --- toxicity --- Dictyosiphon foeniculaceus --- retinal pigment epithelium --- glioblastoma --- astrocytes --- uveal melanoma --- 7-phloro-eckol --- HepG2/CYP2E1 cells --- oxidative stress --- apoptosis --- anti-lung cancer --- brown algae --- human lung carcinoma A-549 cells --- oversulfation --- Sargassum aquifolium --- phlorotannins --- antifungal --- larvicidal --- brown seaweeds --- biological activities --- anti-inflammatory --- antioxidant --- coastal area --- crude lipid extract --- Sargassum ilicifolium --- gut microbiota --- bioaccessibility --- short-chain fatty acids --- prebiotics --- gastrointestinal tract --- noise --- hearing loss --- dieckol --- PFF-A --- alginate --- laminarin --- bioactivity

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Brown algae comprise approx. 2040 species grown in various climatic conditions. They represent a reservoir of various bioactive compounds, including fucoidan, alginate, phlorotannins, and fucoxanthins. They have shown an array of applications in pharmaceutical and medical fields. Hence, the Guest Editor invites all interested authors to submit their contributions to the current issue in Marine Drugs entitled “Bioactive Compounds from Brown Algae”. It aims to highlight different aspects of bioactive compounds found in brown algae, in either research or review articles. Specifically, we are interested in downstream processes, chemistry, biotechnology, and applications of, for example, heteropolysaccharides and other brown algae bioactives. In addition, the structure elucidation and enzymatic modification of these components are also within the scope of the present Issue.

Medicine --- hepatic steatosis --- lipogenesis --- seaweed --- polyphenol --- fucoidans --- fucoidanases --- glycosidic linkages --- molecular masses --- NMR --- structure–activity relationships --- fucoidan --- cancer --- VEGF --- gene expression --- toxicity --- Dictyosiphon foeniculaceus --- retinal pigment epithelium --- glioblastoma --- astrocytes --- uveal melanoma --- 7-phloro-eckol --- HepG2/CYP2E1 cells --- oxidative stress --- apoptosis --- anti-lung cancer --- brown algae --- human lung carcinoma A-549 cells --- oversulfation --- Sargassum aquifolium --- phlorotannins --- antifungal --- larvicidal --- brown seaweeds --- biological activities --- anti-inflammatory --- antioxidant --- coastal area --- crude lipid extract --- Sargassum ilicifolium --- gut microbiota --- bioaccessibility --- short-chain fatty acids --- prebiotics --- gastrointestinal tract --- noise --- hearing loss --- dieckol --- PFF-A --- alginate --- laminarin --- bioactivity --- hepatic steatosis --- lipogenesis --- seaweed --- polyphenol --- fucoidans --- fucoidanases --- glycosidic linkages --- molecular masses --- NMR --- structure–activity relationships --- fucoidan --- cancer --- VEGF --- gene expression --- toxicity --- Dictyosiphon foeniculaceus --- retinal pigment epithelium --- glioblastoma --- astrocytes --- uveal melanoma --- 7-phloro-eckol --- HepG2/CYP2E1 cells --- oxidative stress --- apoptosis --- anti-lung cancer --- brown algae --- human lung carcinoma A-549 cells --- oversulfation --- Sargassum aquifolium --- phlorotannins --- antifungal --- larvicidal --- brown seaweeds --- biological activities --- anti-inflammatory --- antioxidant --- coastal area --- crude lipid extract --- Sargassum ilicifolium --- gut microbiota --- bioaccessibility --- short-chain fatty acids --- prebiotics --- gastrointestinal tract --- noise --- hearing loss --- dieckol --- PFF-A --- alginate --- laminarin --- bioactivity